 David Moreno
Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 11 | 2025 | 125 | 3.220 |
Why?
| | Waldenstrom Macroglobulinemia | 4 | 2023 | 11 | 2.590 |
Why?
| | Lymphoma, B-Cell | 3 | 2023 | 105 | 2.220 |
Why?
| | Saccharomyces cerevisiae | 12 | 2024 | 530 | 2.000 |
Why?
| | Saccharomyces cerevisiae Proteins | 10 | 2023 | 383 | 1.920 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 3 | 1.840 |
Why?
| | Cellular Senescence | 3 | 2024 | 181 | 1.380 |
Why?
| | Proteostasis | 2 | 2020 | 27 | 1.310 |
Why?
| | Molecular Chaperones | 3 | 2019 | 182 | 1.260 |
Why?
| | Plasmacytoma | 2 | 2022 | 16 | 0.980 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2025 | 19 | 0.950 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2025 | 56 | 0.930 |
Why?
| | Translocation, Genetic | 1 | 2025 | 96 | 0.910 |
Why?
| | Chromosome Aberrations | 1 | 2025 | 147 | 0.890 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 32 | 0.770 |
Why?
| | Calcaneus | 1 | 2022 | 31 | 0.760 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 171 | 0.740 |
Why?
| | Myeloid Differentiation Factor 88 | 4 | 2023 | 97 | 0.730 |
Why?
| | Galactokinase | 1 | 2020 | 4 | 0.710 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 87 | 0.710 |
Why?
| | B-Cell Maturation Antigen | 3 | 2025 | 9 | 0.700 |
Why?
| | Immunotherapy, Adoptive | 4 | 2025 | 300 | 0.700 |
Why?
| | Automation | 1 | 2020 | 81 | 0.680 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2025 | 576 | 0.680 |
Why?
| | Epistasis, Genetic | 1 | 2020 | 70 | 0.680 |
Why?
| | Cell Enlargement | 2 | 2019 | 5 | 0.670 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 139 | 0.660 |
Why?
| | Graft vs Host Disease | 2 | 2019 | 240 | 0.650 |
Why?
| | DNA Replication | 2 | 2023 | 227 | 0.650 |
Why?
| | Bone Neoplasms | 1 | 2022 | 229 | 0.650 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2019 | 8 | 0.640 |
Why?
| | Cell Size | 1 | 2019 | 87 | 0.620 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 95 | 0.620 |
Why?
| | Histone Deacetylases | 1 | 2020 | 212 | 0.620 |
Why?
| | Time-Lapse Imaging | 1 | 2019 | 20 | 0.620 |
Why?
| | Intravital Microscopy | 1 | 2019 | 25 | 0.610 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1560 | 0.610 |
Why?
| | Heat-Shock Response | 1 | 2019 | 72 | 0.600 |
Why?
| | Chromatin | 1 | 2020 | 479 | 0.540 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 740 | 0.450 |
Why?
| | Cyclins | 4 | 2021 | 89 | 0.390 |
Why?
| | Smoldering Multiple Myeloma | 2 | 2021 | 2 | 0.380 |
Why?
| | Immunoglobulin M | 3 | 2022 | 276 | 0.370 |
Why?
| | Receptors, CXCR4 | 2 | 2022 | 83 | 0.350 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 2 | 2021 | 7 | 0.340 |
Why?
| | Dexamethasone | 2 | 2025 | 350 | 0.310 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2024 | 752 | 0.310 |
Why?
| | Mutation | 4 | 2023 | 3717 | 0.300 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2019 | 24 | 0.290 |
Why?
| | Protein Biosynthesis | 4 | 2022 | 410 | 0.260 |
Why?
| | Gene Expression Regulation, Fungal | 3 | 2023 | 68 | 0.260 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2025 | 18 | 0.240 |
Why?
| | Bortezomib | 1 | 2025 | 45 | 0.240 |
Why?
| | Thalidomide | 1 | 2025 | 32 | 0.230 |
Why?
| | Humans | 24 | 2025 | 129626 | 0.230 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2025 | 87 | 0.220 |
Why?
| | Histone Acetyltransferases | 1 | 2025 | 60 | 0.220 |
Why?
| | Receptors, Virus | 1 | 2024 | 83 | 0.220 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2025 | 128 | 0.220 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 121 | 0.220 |
Why?
| | Bone Marrow | 2 | 2024 | 273 | 0.220 |
Why?
| | Cell Cycle | 3 | 2023 | 588 | 0.220 |
Why?
| | T-Lymphocytes | 2 | 2025 | 1936 | 0.210 |
Why?
| | Disease-Free Survival | 2 | 2022 | 646 | 0.210 |
Why?
| | Receptors, Immunologic | 1 | 2024 | 217 | 0.210 |
Why?
| | Prognosis | 2 | 2022 | 3774 | 0.190 |
Why?
| | Cell Cycle Proteins | 2 | 2023 | 584 | 0.190 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 5 | 0.190 |
Why?
| | Molecular Dynamics Simulation | 2 | 2020 | 217 | 0.190 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2021 | 8 | 0.190 |
Why?
| | Allografts | 1 | 2022 | 137 | 0.180 |
Why?
| | Immunoglobulin Light Chains | 1 | 2021 | 40 | 0.180 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2021 | 80 | 0.180 |
Why?
| | Cytoplasmic Granules | 1 | 2021 | 78 | 0.180 |
Why?
| | Genes, Regulator | 1 | 2020 | 34 | 0.180 |
Why?
| | Dendritic Spines | 1 | 2021 | 64 | 0.170 |
Why?
| | Models, Biological | 3 | 2024 | 1724 | 0.170 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 88 | 0.170 |
Why?
| | Calibration | 1 | 2020 | 140 | 0.170 |
Why?
| | Niacinamide | 1 | 2020 | 75 | 0.170 |
Why?
| | Feedback, Physiological | 1 | 2020 | 76 | 0.170 |
Why?
| | Epigenomics | 1 | 2020 | 110 | 0.170 |
Why?
| | RNA, Messenger | 2 | 2025 | 2708 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2025 | 10219 | 0.160 |
Why?
| | Small Molecule Libraries | 1 | 2020 | 86 | 0.160 |
Why?
| | Polymerase Chain Reaction | 1 | 2022 | 1035 | 0.160 |
Why?
| | Photopheresis | 1 | 2019 | 9 | 0.160 |
Why?
| | Drug Discovery | 1 | 2020 | 130 | 0.160 |
Why?
| | S Phase Cell Cycle Checkpoints | 1 | 2019 | 4 | 0.160 |
Why?
| | Cell Nucleolus | 1 | 2019 | 17 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 958 | 0.160 |
Why?
| | Luminescent Agents | 1 | 2019 | 7 | 0.160 |
Why?
| | Actins | 1 | 2021 | 411 | 0.150 |
Why?
| | Acute Disease | 2 | 2019 | 979 | 0.150 |
Why?
| | Aged | 8 | 2025 | 22061 | 0.150 |
Why?
| | Spatio-Temporal Analysis | 1 | 2019 | 26 | 0.150 |
Why?
| | Cyclin G1 | 1 | 2018 | 1 | 0.150 |
Why?
| | Lymphoma | 1 | 2020 | 199 | 0.150 |
Why?
| | Transcription, Genetic | 1 | 2025 | 1418 | 0.150 |
Why?
| | Cell Growth Processes | 1 | 2018 | 52 | 0.150 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 69 | 0.150 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 281 | 0.150 |
Why?
| | Spectrometry, Fluorescence | 1 | 2019 | 163 | 0.150 |
Why?
| | Centromere | 1 | 2018 | 48 | 0.150 |
Why?
| | Genomics | 1 | 2023 | 718 | 0.150 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2019 | 129 | 0.140 |
Why?
| | Adenosine Triphosphatases | 1 | 2019 | 161 | 0.140 |
Why?
| | Middle Aged | 9 | 2025 | 31136 | 0.140 |
Why?
| | Luminescent Proteins | 1 | 2019 | 176 | 0.140 |
Why?
| | Stress, Physiological | 1 | 2021 | 414 | 0.140 |
Why?
| | Models, Molecular | 2 | 2020 | 1491 | 0.140 |
Why?
| | Biological Evolution | 1 | 2020 | 436 | 0.130 |
Why?
| | Skin Diseases | 1 | 2018 | 143 | 0.130 |
Why?
| | Pleural Effusion | 1 | 2017 | 52 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1488 | 0.130 |
Why?
| | Male | 10 | 2025 | 63670 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 617 | 0.120 |
Why?
| | Chronic Disease | 2 | 2019 | 1720 | 0.120 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1308 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1366 | 0.120 |
Why?
| | Endoplasmic Reticulum | 1 | 2017 | 261 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1432 | 0.110 |
Why?
| | Female | 10 | 2025 | 68734 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 580 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2641 | 0.090 |
Why?
| | Adult | 5 | 2025 | 35599 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7052 | 0.090 |
Why?
| | Signal Transduction | 2 | 2022 | 4931 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 213 | 0.090 |
Why?
| | Molecular Conformation | 2 | 2020 | 141 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2046 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3186 | 0.070 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1164 | 0.060 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2025 | 30 | 0.060 |
Why?
| | Nectins | 1 | 2024 | 5 | 0.060 |
Why?
| | RNA Stability | 1 | 2025 | 103 | 0.060 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2023 | 41 | 0.050 |
Why?
| | RNA Splicing | 1 | 2025 | 260 | 0.050 |
Why?
| | Adolescent | 1 | 2022 | 20412 | 0.050 |
Why?
| | Longevity | 1 | 2023 | 155 | 0.050 |
Why?
| | Biological Transport | 1 | 2023 | 404 | 0.050 |
Why?
| | Child | 1 | 2022 | 20884 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 274 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2022 | 149 | 0.050 |
Why?
| | Recurrence | 1 | 2025 | 1011 | 0.050 |
Why?
| | Iron | 1 | 2023 | 282 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4894 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2021 | 220 | 0.050 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 83 | 0.040 |
Why?
| | Trans-Activators | 1 | 2023 | 393 | 0.040 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2021 | 29 | 0.040 |
Why?
| | History, 21st Century | 1 | 2021 | 186 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 282 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 104 | 0.040 |
Why?
| | Databases, Protein | 1 | 2020 | 61 | 0.040 |
Why?
| | History, 20th Century | 1 | 2021 | 294 | 0.040 |
Why?
| | Molecular Weight | 1 | 2020 | 329 | 0.040 |
Why?
| | Quantum Theory | 1 | 2020 | 82 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 202 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 213 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2019 | 16 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2019 | 42 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 307 | 0.040 |
Why?
| | HeLa Cells | 1 | 2021 | 612 | 0.040 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 101 | 0.040 |
Why?
| | Glucose | 1 | 2024 | 1002 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 406 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2021 | 279 | 0.040 |
Why?
| | Rituximab | 1 | 2019 | 164 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1269 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1705 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 621 | 0.040 |
Why?
| | G1 Phase | 1 | 2018 | 70 | 0.040 |
Why?
| | Saccharomycetales | 1 | 2018 | 26 | 0.040 |
Why?
| | Mice | 2 | 2025 | 16961 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1282 | 0.040 |
Why?
| | Proteolysis | 1 | 2018 | 167 | 0.040 |
Why?
| | Piperidines | 1 | 2019 | 201 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 588 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 258 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 851 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 596 | 0.030 |
Why?
| | Cell Division | 1 | 2018 | 796 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1202 | 0.030 |
Why?
| | Pyrazoles | 1 | 2019 | 404 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 477 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 459 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1336 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2542 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1647 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 160 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1269 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2124 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1872 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4078 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 400 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 944 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1465 | 0.030 |
Why?
| | Disease Progression | 1 | 2021 | 2627 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1042 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1198 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2018 | 660 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3075 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 642 | 0.030 |
Why?
| | Animals | 2 | 2025 | 35391 | 0.030 |
Why?
| | Neurons | 1 | 2021 | 1494 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 1875 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5426 | 0.020 |
Why?
| | Pneumonia | 1 | 2017 | 617 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7135 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6555 | 0.020 |
Why?
| | Child, Preschool | 1 | 2017 | 10490 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 14522 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|